Avid Bioservices Inc (CDMO)

[freethemice]

Jason Stafford's Ph.D. dissertation from 2011 is available online.
http://repositories.tdl.org/utswmed-ir/handle/2152.5/1038
Here is the concluding paragraph from chapter 3, followed by Figure 3.6. Note that 124I-IN11 F(ab')2
is now renamed as the imaging agent 124I-PGN650.

The most important clinical use for 124I-1N11 F(ab’ )2 to translate the clinic
may not be for early diagnosis of cancer, but rather for assessing tumor response
to therapy. PS externalized on apoptotic and necrotic tumor cells after anti-tumor
therapy should result in increased 124I-1N11 F(ab’ )2 uptake in responding tumors.
Future studies will be aimed at determining if increased uptake of 124I-1N11
F(ab’ )2 in tumors treated with chemotherapy, radiation therapy, and/or androgen
deprivation therapy can be used to predict the effect of each therapy on tumor
growth.

Figure 3.6. PET imaging of subcutaneous PC3 tumors with 124I-1N11
F(ab’)2. At 48 hr p.i., subcutaneous PC3 tumors (arrow) were clearly delineated
by 124I-1N11 F(ab’ )2. Signal in heart is from blood pool. Signal from the bladder
was subtracted during image analysis. 124I-Aurexis F(ab’ )2 (ctrl) did not label
tumors.